FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 589 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant... September 19, 2024 EMA Recommends Extension of Therapeutic Indications for Selinexor June 15, 2022 How and When to Wash Your Reusable Cloth Mask and When... November 30, 2020 What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials December 6, 2023 Load more HOT NEWS Transforming Cancer Clinical Trials for Better, Faster Results New independent tobacco review sets roadmap for a smokefree England for... Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple...
